BELLUS Health Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLU research report →
Companywww.bellushealth.com
BELLUS Health Inc. , a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.
- CEO
- Roberto Francesco Bellini
- IPO
- 2000
- Employees
- 74
- HQ
- Laval, QC, CA
Price Chart
Valuation
- Market Cap
- $1.87B
- P/E
- -21.47
- P/S
- 112213.28
- P/B
- 4.18
- EV/EBITDA
- -23.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -486768.75%
- Net Margin
- -475500.00%
- ROE
- -22.28%
- ROIC
- -19.85%
Growth & Income
- Revenue
- $16.00K · 0.00%
- Net Income
- $-76,080,000 · -6.82%
- EPS
- $-0.66 · 26.67%
- Op Income
- $-77,883,000
- FCF YoY
- -40.95%
Performance & Tape
- 52W High
- $14.76
- 52W Low
- $6.38
- 50D MA
- $14.40
- 200D MA
- $10.11
- Beta
- -0.28
- Avg Volume
- 5.38M
Get TickerSpark's AI analysis on BLU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BLU Coverage
We haven't published any research on BLU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BLU Report →